Antibodies

17 Jan 2023 Leap Therapeutics Acquires Flame Biosciences
17 Jan 2023 Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors
17 Jan 2023 Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III
16 Jan 2023 China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)
16 Jan 2023 Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application
16 Jan 2023 A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe
13 Jan 2023 Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
13 Jan 2023 Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 Antibody by the U.S. FDA
12 Jan 2023 Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
11 Jan 2023 Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
11 Jan 2023 Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases
11 Jan 2023 Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
11 Jan 2023 Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia
10 Jan 2023 Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
09 Jan 2023 Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
09 Jan 2023 Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines
09 Jan 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
09 Jan 2023 Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
07 Jan 2023 HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
07 Jan 2023 Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
07 Jan 2023 Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
07 Jan 2023 FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
06 Jan 2023 Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
06 Jan 2023 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
06 Jan 2023 FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top